The healthcare industry is ripe for disruption.

View Hims & Hers Health, Inc. Class A HIMS stock quote prices, financial information, real-time forecasts, and company news from CNN.

Shares of Hims & Hers Health, Inc. HIMS are trading higher on Thursday as investors react to a new chief medical leadership ...

Hims & Hers has been one of the most closely watched names in digital health this month. Between the FDA's peptide announcement, a Novo Nordisk settlement, and a flood of analyst revisions, the stock ...

Learn more CEO Andrew Dudum called Anthropic's latest AI breakthrough "transformative" for population health, saying AI is ...

This telehealth stock has fallen hard, but its GLP-1 shift and global expansion could reshape the long-term story. Is the market too skeptical or still too optimistic?

Is HIMS a good stock to buy? We came across a bearish thesis on Hims & Hers Health, Inc. on Valueinvestorsclub.com by Pridwen ...

Shares of telehealth company Hims & Hers skyrocketed Monday after the company struck a deal with Danish drugmaker Novo Nordisk to sell its GLP-1 weight-loss medications, ending the feud between the ...

The average one-year price target for Hims & Hers Health (NYSE:HIMS) has been revised to $30.00 / share. This is a decrease of 30.94% from the prior estimate of $43.45 dated February 1, 2026. The ...

Hims & Hers also said it is shifting its U.S. weight-loss business away from actively advertising compounded GLP-1 drugs and toward a wider assortment of FDA-approved treatments. Existing patients may ...